Skip to main content
. 2020 Sep 7;8(1):e001221. doi: 10.1136/bmjdrc-2020-001221

Figure 5.

Figure 5

Microvessel density and maturity. (A) Representative high power field sections of the wound bed, day 10. CD31, α-SMA, DAPI, and merged immunofluorescent stained sections of the wound bed of wounds treated with MSA, ATZ, and occlusive dressing (Chronic diabetic), wounds treated with MSA, ATZ, a collagen-glycosaminoglycan implant plus occlusive dressing (Treated chronic diabetic), and wounds covered with occlusive dressing (Diabetic control) on day 10. Square insert highlights the CD31-α-SMA architecture in each group. Scale bar=µ100 m. (B) Microvessel density, day 10. Based on a sample of 10 mice per group, a significant difference in microvessel density was shown between the Diabetic control group and both ATZ+MSA treated groups. (C) Microvessel maturity, day 10. A significant difference in microvessel maturity was shown between the Diabetic control group and both ATZ+MSA treated groups. (D) Representative high power field sections, day 5 and day 28. CD31+α-SMA-stained wound bed sections of wounds treated with ATZ, MSA, and occlusive dressing (Chronic diabetic), wounds treated with ATZ, MSA, a collagen-glycosaminoglycan implant plus occlusive dressing (Treated chronic diabetic), and wounds covered with occlusive dressing (Diabetic control) on day 5 and day 28. *p<0.05, **p<0.01, ***p<0.001. ATZ, 3-amino-1,2,4-triazole; DAPI, 4',6-diamidino-2 phenylindole; HPF, high power field; MSA, mercaptosuccinic acid; α-SMA, α-smooth muscle actin antibody.